and a refreshingly realistic and rational summation of CM8’s...

First 63 Last

Share
Profile

Follow
colgm

1,524 Posts.

441

30/12/20

12:04

Post #: 49861860
Share

Originally posted by huntfish: ↑

Small volumes for sure, but definitely the right direction
I think most can see the benefit of not that many shares on the register in comparison to so many specs in the billions of shares
Small volumes can shift our stock very fast
Volume will come eventually as the team continues to execute on their horizons and I believe most of us can see just how fast our share price will appreciate when these milestones are reached
Right now we have a team that is ticking every box and delivering on what they’ve preached to their shareholders which makes me confident in just sitting tight for the foreseeable future if they continue on the same path
At 20c we will still only have a market cap of $100m which isn’t at all unreasonable when you look down this end thoroughly, especially if our earnings have reached the inflection point of beginning to appreciate north of the $15m annualised revenue generated last quarter
And yes, just like literally every spec stock there are options to convert, but not a crazy amount and they will just increase money in the bank to help fuel growth ensuring no more capital raising which will create more strength in the stock as investors won’t have that on their mind when choosing to invest in Crowd
Then add in the cherry on top like any spec stock needs for a rerate and that is, blue sky ahead
Something to get excited about
And Crowd has that in spades with their H2 (fintech & Insuretech) & H3 (talking heads conversational commerce)
Just a matter of time now on both as we have been advised the real work has already taken place behind the scenes and the team is ahead in every aspect of delivering on these initiatives in 2021
2021 will be a significant year for Crowd and we as shareholders get to enjoy seeing our team deliver which will mean a rising share price

Expand

and a refreshingly realistic and rational summation of CM8’s near future. No sugar added.

as in life one does not get rewarded on potential.

Hopefully more than just a step change in performance expected in January will provide shareholders with new year joy.

CM8 Price at posting: 5.2¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

RXL

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 159 more messages in this thread...

First 63 Last

Add UNT (ASX) to my watchlist

(20min delay)
Last 1.7¢		Change 0.000(0.00%)		Mkt cap ! $20.88M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	165582	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.8¢	340000	4

View Market Depth

No.	Vol.	Price($)
1	165582	0.017
8	3877500	0.016
6	1620000	0.015
4	2151225	0.014
5	1355389	0.013

Price($)	Vol.	No.
0.018	340000	4
0.019	1115000	4
0.020	1788888	6
0.021	1398041	8
0.022	1068755	2

Last trade - 07.00am 04/10/2024 (20 minute delay)

UNT (ASX) Chart

Day chart unavailable

and a refreshingly realistic and rational summation of CM8’s...

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

and a refreshingly realistic and rational summation of CM8’s...

Top Stories

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News